Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.

NCT06388551 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.

NCT NCT06388551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.
Lead sponsor
Luye Pharma Group Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 10, 2024
Completion date
March 30, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hallucinations and delusions associated with alzheimer's disease psychosis, hallucinations and delusions associated with parkinson disease psychosis, negative symptoms of schizophrenia